Skip to main content

Aldeyra Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

ALDX$0.63+2.9%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Consolidated Balance Sheets at June 30, 2025 (Unaudited) and December 31, 2024

CONSOLIDATED BALANCE SHEETS

June 30,
2025December 31,
(unaudited)2024
ASSETS
Current assets:
Cash and cash equivalents$41,241,269$54,527,092
Marketable securities40,678,37046,624,180
Prepaid expenses and other current assets2,638,5892,921,206
Total current assets84,558,228104,072,478
Deferred offering costs—267,261
Right-of-use assets404,660266,955
Total assets$84,962,888$104,606,694
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$1,455,271$180,453
Accrued expenses6,663,58012,118,367
Current portion of debt15,148,89731,372
Operating lease liabilities263,551271,631
Deferred collaboration revenue6,000,0006,000,000
Total current liabilities29,531,29918,601,823
Operating lease liabilities, long-term143,447—
Long-term debt, net of current portion—15,000,000
Total liabilities29,674,74633,601,823
Commitments and contingencies (Notes 3, 9, & 14)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding——
Common stock, voting, $0.001 par value; 150,000,000 authorized and 60,045,530 and 59,648,278 shares issued and outstanding, respectively60,04659,648
Additional paid-in capital525,046,496521,018,373
Accumulated other comprehensive (loss) income(10,995)37,442
Accumulated deficit(469,807,405)(450,110,592)
Total stockholders’ equity55,288,14271,004,871
Total liabilities and stockholders’ equity$84,962,888$104,606,694
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.